Dr Gilbert On Evaluating Mirvetuximab Soravtansine In Platinum Lucy gilbert, md, msc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum agnostic ovarian cancer. Evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum resistant ovarian cancer.
Mirvetuximab Soravtansine Gynx Elahere邃 Immunogen Purpose: evaluate the antitumor activity and safety profile of the combination of mirvetuximab soravtansine and bevacizumab in patients with platinum resistant ovarian cancer. Gilbert l., et al., safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (fralpha) targeting antibody drug conjugate (adc), in combination with bevacizumab in patients with platinum resistant ovarian cancer. Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status. Lucy gilbert, md, msc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum agnostic ovarian cancer.
Mirvetuximab Soravtansine Semantic Scholar Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum agnostic ovarian cancer demonstrated encouraging overall response rates regardless of platinum status. Lucy gilbert, md, msc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum agnostic ovarian cancer. Lucy gilbert, md, msc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high grade epithelial ovarian cancer regardless of platinum sensitivity. Seven studies involving 631 patients were analyzed to evaluate the efficacy and safety of mirvetuximab soravtansine in treating advanced platinum sensitive or platinum resistant recurrent oc with fra positive expression. “dr. (david m.) o’malley and i, on behalf of our co authors, are very pleased that, in mirvetuximab soravtansine, women with folate receptor α platinum resistant ovarian cancer now have a highly effective treatment option,” said dr. gilbert upon receiving the award in san diego. Evaluate the antitumor activity and safety prole of the triplet combination of mirvetuximab fi soravtansine (mirv), carboplatin, and bevacizumab in recurrent, platinum sensitive ovarian cancer. methods.